Publicaciones en las que colabora con José Manuel García Pinilla (16)

2023

  1. Dapagliflozin and short-term changes on circulating antigen carbohydrate 125 in heart failure with reduced ejection fraction

    Scientific Reports, Vol. 13, Núm. 1

  2. Impact of dapagliflozin on cardiac remodelling in patients with chronic heart failure: The DAPA-MODA study

    European Journal of Heart Failure, Vol. 25, Núm. 8, pp. 1352-1360

  3. Optimization of Patient Pathway in Heart Failure with Reduced Ejection Fraction and Worsening Heart Failure. Role of Vericiguat

    Patient Preference and Adherence, Vol. 17, pp. 839-849

  4. Short-Term Changes in Peak VO2 After Initiation of Dapagliflozin in Heart Failure Across Iron Status

    JACC: Heart Failure, Vol. 11, Núm. 11, pp. 1611-1622

2022

  1. Prevalence, Incidence, and Outcomes of Hyperkalaemia in Patients with Chronic Heart Failure and Reduced Ejection Fraction from a Spanish Multicentre Study: SPANIK-HF Design and Baseline Characteristics

    Journal of Clinical Medicine, Vol. 11, Núm. 5

  2. Short-term effects of dapagliflozin on maximal functional capacity in heart failure with reduced ejection fraction (DAPA-VO2): a randomized clinical trial

    European Journal of Heart Failure, Vol. 24, Núm. 10, pp. 1816-1826

2020

  1. Expert consensus statement on heart failure with reduced ejection fraction: beyond the guidelines

    Revista Espanola de Cardiologia Suplementos, Vol. 20, Núm. SB, pp. 1-46

  2. Hyperkalemia in heart failure patients in Spain and its impact on guidelines and recommendations: ESC-EORP-HFA Heart Failure Long-Term Registry

    Revista Espanola de Cardiologia, Vol. 73, Núm. 4, pp. 313-323

  3. NT-proBNP Response to Sacubitril/Valsartan in Hospitalized Heart Failure Patients With Reduced Ejection Fraction: TRANSITION Study

    JACC: Heart Failure, Vol. 8, Núm. 10, pp. 822-833

  4. Pronóstico al año en pacientes con insuficiencia cardiaca en España. Registro ESC-EORP-HFA Heart Failure Long-Term

    REC: CardioClinics, Vol. 55, Núm. 4, pp. 207-216

2019

  1. Genetic Variants Associated With Cancer Therapy-Induced Cardiomyopathy

    Circulation, Vol. 140, Núm. 1, pp. 31-41

  2. Sacubitril/valsartan eligibility and outcomes in the ESC-EORP-HFA Heart Failure Long-Term Registry: bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGM-HF trial, ESC guidelines, and real world

    European Journal of Heart Failure, Vol. 21, Núm. 11, pp. 1383-1397

2018

  1. Efficacy and safety of intermittent intravenous outpatient administration of levosimendan in patients with advanced heart failure: the LION-HEART multicentre randomised trial

    European Journal of Heart Failure, Vol. 20, Núm. 7, pp. 1128-1136

  2. Genetic Etiology for Alcohol-Induced Cardiac Toxicity

    Journal of the American College of Cardiology, Vol. 71, Núm. 20, pp. 2293-2302

  3. Performance of Prognostic Risk Scores in Chronic Heart Failure Patients Enrolled in the European Society of Cardiology Heart Failure Long-Term Registry

    JACC: Heart Failure, Vol. 6, Núm. 6, pp. 452-462

2013

  1. Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12 440 patients of the ESC Heart Failure Long-Term Registry

    European Journal of Heart Failure, Vol. 15, Núm. 10, pp. 1173-1184